Clinical Trial

Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia

Study acronym: HIATUS
Recruiting
View on ClinicalTrials.gov →
Summary
The large hiatal hernia (LHH) now represents approximately 50% of laparoscopic antireflux surgical practice. In a non-comparative retrospective study of 399 patients operated for LHH with onlay patch of a bioprosthetic absorbable (Gore® Bio-A® HH0710) mesh with a mean follow-up of 44 months, 16% had a symptomatic recurrence with 7,9% requiring reoperation, one patient had oesophageal stenosis. No comparative effectiveness data exist to date. Hypothesis: the incidence of postoperative hiatus hernia would be reduced by the addition of biosynthetic absorbable mesh reinforcement to a standardized suture repair technique, as compared to laparoscopic repair without mesh, without increasing the risk of complications. The main objective is to compare the radiologic recurrence rate at 2 years between standardized herniorrhaphy with onlay biosynthetic absorbable mesh repair versus standardized herniorrhaphy with no mesh in symptomatic LHH.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-16.
Status change: Not Yet Recruiting → Recruiting 2024-01-17
Trial Details
NCT Number NCT05867225
Lead Sponsor University Hospital, Bordeaux
Conditions Large Hiatal Hernia
Enrollment 256 participants
Start Date 2024-01-15
Primary Completion 2028-01-18 (estimated)
Study Completion 2028-01-18 (estimated)
Updated on ClinicalTrials.gov 2024-01-18